The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A Phase I/Ib study of MEK162 (binimetinib), a MEK inhibitor, in combination with carboplatin and pemetrexed in patients with non-squamous NSCLC.
 
Safiya Karim
No Relationships to Disclose
 
Ronald Feld
No Relationships to Disclose
 
Natasha B. Leighl
Research Funding - Novartis (Inst)
 
Frances A. Shepherd
Stock and Other Ownership Interests - AstraZeneca; Lilly
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; Merck/Schering Plough; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Recombio; Synta
Research Funding - Boehringer Ingelheim (Inst)
 
Penelope Ann Bradbury
No Relationships to Disclose
 
Geoffrey Liu
No Relationships to Disclose
 
Donna M. Graham
No Relationships to Disclose